{
  "id": 14428625,
  "title": "Pfizer to present infectious disease data at IDWeek 2026",
  "url": "https://urgent.news/2026/10/14/pfizer-to-present-infectious-disease-data-at-idweek-2026",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T10:52:37.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/pfizer-to-present-infectious-disease-data-at-idweek-2026-93CH-4948748"
  },
  "original_language": "en",
  "account": null,
  "summary": "Pfizer Inc. is set to present a wealth of infectious disease data at the IDWeek 2026 congress, scheduled for October 21-24 in Washington, D.C. The company will showcase 12 oral presentations covering its infectious disease pipeline and portfolio, including data on pneumococcal disease, respiratory syncytial virus, Lyme disease, COVID-19, and meningococcal vaccines. Key highlights include late-breaking Phase 2 data comparing Pfizer’s 25-valent pneumococcal conjugate vaccine candidate with PREVNAR 20 in healthy infants, and Phase 3 results from the VALOR study on a 6-valent Lyme disease vaccine candidate. Additionally, Pfizer will present real-world data on its RSV vaccine, ABRYSVO, and effectiveness data for PREVNAR 20 against invasive pneumococcal disease in U.S. adults 65 years and older.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}